Bioporto AS (FRA:2P4) Quality Rank


FRA:2P4 Bioporto AS FRA:2P4
70 GF Score
Price €0.13
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Bioporto AS Quality Rank Related Terms

FRA:2P4
70GF Score
Bioporto AS FRA:2P4
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioporto AS (FRA:2P4) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of €0.13 is trading 14% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:2P4:

  • Quality Rank:
  • GF Value™: €0.15 vs. price of €0.13 (14% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the FRA:2P4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
70GF Score

Get the complete analysis for FRA:2P4

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.15
GF Value